(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

TALL

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

TALL

ST13

US500000090688104

Class

42

Filing

90688104

Registration

7323222

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

34

Latest update

03/05/2024

Trademark type

Word

Nice classes

42

Filing date

05/03/2021

Registration date

03/05/2024

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/05/2024

Last transaction

03/05/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

11/09/2019

First use in commerce

11/09/2019

Drawing code

4

Owner type

99

Owner location

Menlo Park, CA

Examiner

ABID, NABEELA

Law office

M40

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

S. I. (pessoa física)

Representatives

B. Anna McCoy MCCOY RUSSELL LLP

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Medical and pharmacological research services in the field of immunotherapy and cancer treatment; biological researchclinical researchmedical research all in the field of immunotherapies and cancer treatment; development of drug delivery agents being made from liposomes and peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations

Publications

History of USPTO decisions and trademark events.

34 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/05/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

03/05/2024

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

01/27/2024

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

01/26/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/26/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/25/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

01/25/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

10/25/2023

GNRT

NON-FINAL ACTION E-MAILED

10/25/2023

CNRT

SU - NON-FINAL ACTION - WRITTEN

10/25/2023

SUPC

STATEMENT OF USE PROCESSING COMPLETE

10/25/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

10/25/2023

IUAF

USE AMENDMENT FILED

10/12/2023

EISU

TEAS STATEMENT OF USE RECEIVED

10/12/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

04/14/2023

EX2G

SOU EXTENSION 2 GRANTED

04/12/2023

EXT2

SOU EXTENSION 2 FILED

04/12/2023

EEXT

SOU TEAS EXTENSION RECEIVED

04/12/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

09/29/2022

EX1G

SOU EXTENSION 1 GRANTED

09/27/2022

EXT1

SOU EXTENSION 1 FILED

09/27/2022

EEXT

SOU TEAS EXTENSION RECEIVED

09/27/2022

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

04/12/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/15/2022

PUBO

PUBLISHED FOR OPPOSITION

02/15/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

01/26/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/12/2022

XAEC

EXAMINER'S AMENDMENT ENTERED

01/12/2022

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

01/12/2022

GNEA

EXAMINERS AMENDMENT E-MAILED

01/12/2022

CNEA

EXAMINERS AMENDMENT -WRITTEN

01/12/2022

DOCK

ASSIGNED TO EXAMINER

01/04/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/05/2021

NWAP

NEW APPLICATION ENTERED

05/06/2021

Continuous trademark protection

Get notified about every new filing that threatens TALL or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.